Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for ARO-INHBE in Obesity, Metabolic disorder. The expected timing is based on the latest available company guidance and may change.
9/23/24 Files for Regulatory Clearance. 12/23/24- Trial initiated. 11/25/25:- PR No update. 01/06/26:- AROINHBE-1001 interim Ph1/2a data showed strong visceral and liver fat reductions; additional results expected in 2026. 05/27/26:- EASL 2026 interim data showed liver-fat reductions, including with low-dose tirzepatide. Regulators engaged on Ph2 designs.
Verification
Confirm timing and program details against the company announcement or filing.